Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032233 | 0.90 | MEN1 (0.46) | MEN1KMT2AMAPK7PDE3BPDE3A | |
| SCHEMBL19032166 | 0.77 | PDE3B (0.39) | MEN1KMT2AMAPK7PDE3BPDE3A | |
| SCHEMBL19049712 | 0.76 | HTT (0.61) | MEN1KMT2AMAPK7PDE3BPDE3A | |
| SCHEMBL30543218 | 0.74 | AKT2 (0.46) | MAPK7PDE3BPDE3A | |
| SCHEMBL19049680 | 0.73 | MAPK7 (0.58) | MAPK7 | |
| SCHEMBL16090525 | 0.71 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19032180 | 0.71 | PDE3B (0.42) | MAPK7PDE3BPDE3A | |
| SCHEMBL19049700 | 0.71 | PDGFRB (0.51) | MAPK7 | |
| SCHEMBL16090460 | 0.70 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17775475 | 0.70 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | MEN1 1/4885KMT2A 218/4885MAPK7 2172/4885 |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | MEN1 1/4885KMT2A 176/4885MAPK7 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.